while the 36-month beta value is 1.17.Analysts have differing opinions on the stock, with 11 analysts rating it as a “buy,” 0 as “overweight,” 10 as “hold,” and 0 as “sell.”
The average price point forecasted by analysts for Sage Therapeutics Inc. (SAGE) is $61.56, which is $4.72 above the current market price. The public float for SAGE is 52.05M, and currently, short sellers hold a 10.78% ratio of that floaft. The average trading volume of SAGE on June 16, 2023 was 509.20K shares.
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, “Top 5 EV Tech Stocks to Buy for 2023”.
SAGE) stock’s latest price update
Sage Therapeutics Inc. (NASDAQ: SAGE) has seen a decline in its stock price by -3.34 in relation to its previous close of 58.04. However, the company has experienced a -1.06% decline in its stock price over the last five trading sessions. Barron’s reported on 02/16/22 that Sage Antidepressant Trial Hits Its Target. Why the Stock Is Down.
SAGE’s Market Performance
SAGE’s stock has fallen by -1.06% in the past week, with a monthly rise of 8.97% and a quarterly rise of 28.55%. The volatility ratio for the week is 4.16% while the volatility levels for the last 30 days are 3.86% for Sage Therapeutics Inc. The simple moving average for the last 20 days is 5.25% for SAGE stock, with a simple moving average of 31.24% for the last 200 days.
Analysts’ Opinion of SAGE
Many brokerage firms have already submitted their reports for SAGE stocks, with RBC Capital Mkts repeating the rating for SAGE by listing it as a “Outperform.” The predicted price for SAGE in the upcoming period, according to RBC Capital Mkts is $60 based on the research report published on March 13th of the current year 2023.
SAGE Trading at 13.09% from the 50-Day Moving Average
After a stumble in the market that brought SAGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.48% of loss for the given period.
Volatility was left at 3.86%, however, over the last 30 days, the volatility rate increased by 4.16%, as shares surge +7.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +38.01% upper at present.
During the last 5 trading sessions, SAGE fell by -1.06%, which changed the moving average for the period of 200-days by +42.46% in comparison to the 20-day moving average, which settled at $53.49. In addition, Sage Therapeutics Inc. saw 47.09% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at SAGE starting from Barrett Elizabeth, who purchase 1,000 shares at the price of $50.50 back on May 09. After this action, Barrett Elizabeth now owns 1,000 shares of Sage Therapeutics Inc., valued at $50,500 using the latest closing price.
JONAS JEFFREY M, the Director of Sage Therapeutics Inc., sale 11,643 shares at $44.61 during a trade that took place back on Feb 10, which means that JONAS JEFFREY M is holding 121,981 shares at $519,413 based on the most recent closing price.
Stock Fundamentals for SAGE
Current profitability levels for the company are sitting at:
- -7116.69 for the present operating margin
- +74.82 for the gross margin
The net margin for Sage Therapeutics Inc. stands at -6931.88. The total capital return value is set at -36.32, while invested capital returns managed to touch -35.55. Equity return is now at value -42.30, with -39.40 for asset returns.
Based on Sage Therapeutics Inc. (SAGE), the company’s capital structure generated 0.97 points at debt to equity in total, while total debt to capital is 0.96. Total debt to assets is 0.89, with long-term debt to equity ratio resting at 0.36. Finally, the long-term debt to capital ratio is 0.36.
When we switch over and look at the enterprise to sales, we see a ratio of 234.94, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 0.48 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.47.
In a nutshell, Sage Therapeutics Inc. (SAGE) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.